Friday, January 27, 2023
Evotec SE announced a strategic collaboration and licence agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration mainly focuses on the development of first-in-class targeted immune-based therapies for oncology, which will ultimately be commercialised by Janssen. The agreement was facilitated by Johnson & Johnson Innovation.
The collaboration leverages Evotec’s integrated discovery and development capabilities and manufacturing optimisation processes, including an option for the GMP manufacture of the immune-based therapies. Evotec will closely collaborate with Janssen during the pre-clinical R&D phase while Janssen will assume full responsibility for the clinical development and commercialisation.
In addition to the research funding, Evotec is entitled to an undisclosed upfront payment, success-based research and commercial milestones exceeding US$350 m as well as tiered royalties on products resulting from the collaboration.
